AllianceBernstein’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-393,782
| Closed | -$29.6M | – | 3332 |
|
|
2022
Q2 | $29.6M | Sell |
393,782
-1,641,267
| -81% | -$72.9M | 0.01% | 725 |
|
|
2022
Q1 | $54.6M | Buy |
2,035,049
+25,858
| +1% | +$869K | 0.02% | 575 |
|
|
2021
Q4 | $95.8M | Buy |
2,009,191
+756,418
| +60% | +$33.8M | 0.03% | 452 |
|
|
2021
Q3 | $83.2M | Sell |
1,252,773
-185,633
| -13% | -$13.2M | 0.03% | 476 |
|
|
2021
Q2 | $112M | Buy |
1,438,406
+382,520
| +36% | +$28.3M | 0.05% | 395 |
|
|
2021
Q1 | $99.9M | Buy |
1,055,886
+110,475
| +12% | +$13.1M | 0.04% | 404 |
|
|
2020
Q4 | $115M | Sell |
945,411
-133,685
| -12% | -$14.6M | 0.05% | 332 |
|
|
2020
Q3 | $94.3M | Sell |
1,079,096
-63,575
| -6% | -$4.43M | 0.05% | 341 |
|
|
2020
Q2 | $73.8M | Buy |
1,142,671
+537,113
| +89% | +$31M | 0.04% | 413 |
|
|
2020
Q1 | $27M | Buy |
605,558
+55,901
| +10% | +$2.97M | 0.02% | 598 |
|
|
2019
Q4 | $34.2M | Buy |
549,657
+101,029
| +23% | +$4.81M | 0.02% | 647 |
|
|
2019
Q3 | $16.9M | Buy |
448,628
+49,192
| +12% | +$2.14M | 0.01% | 860 |
|
|
2019
Q2 | $16.3M | Buy |
+399,436
| New | +$14.2M | 0.01% | 878 |
|
AllianceBernstein's TPTX Position: Q3 2022 in Review
AllianceBernstein sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 393,782 shares — an estimated $29.6M sold.
AllianceBernstein first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $115M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- AllianceBernstein reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- AllianceBernstein sold 393,782 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $29.6M.
- AllianceBernstein first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- AllianceBernstein's Turning Point Therapeutics, Inc. Common Stock position peaked at $115M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on AllianceBernstein's 13F filing for Q3 2022, filed 15 Nov 2022.